Epoprostenol in primary pulmonary hypertension

Annals of Pharmacotherapy

Volumn 33, Issue 3, 1999, Pages 340-347

  Herner, Sheryl J ^a   Mauro, Laurie S ^b,c  

^a UNIVERSITY OF WYOMING   (United States)

^b UNIVERSITY OF TOLEDO   (United States)

^c MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Epoprostenol; Primary pulmonary hypertension

Indexed keywords

PROSTACYCLIN;

ARTICLE; BRADYCARDIA; DRUG EFFECT; DRUG EFFICACY; DYSPNEA; FATIGUE; FLUSHING; HEADACHE; HUMAN; HYPOTENSION; LUNG TRANSPLANTATION; NAUSEA; PATHOPHYSIOLOGY; PATIENT EDUCATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; VOMITING; WELLBEING;

ANTIHYPERTENSIVE AGENTS; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY;

EID: 0345040228     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.17339     Document Type: Article

References (23)

1. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:216-23.
2. Rubin LJ. ACCP consensus statement: primary pulmonary hypertension. Chest 1993;104:236-50.
3. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336: 111-7.
4. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991;115:343-9.
5. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: a natural history and the importance of thrombosis. Circulation 1984;70:580-7.
6. Rubin LJ. Pathology and pathophysiology of primary pulmonary hypertension. Am J Cardiol 1995;75(suppl):51A-4A.
7. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
8. Fishman AP. Pulmonary hypertension. In: Schlant RC, Alexander RW, eds. The heart, arteries and veins. 8th ed. New York: McGraw-Hill, Inc., 1994:1857-74.
9. Butt AY, Higenbottam T. New therapies for primary pulmonary hypertension. Chest 1994;105(suppl 2):21S-5S.
10. Galiè N, Ussia G, Passarelli P, Parlangeli R, Branzi A, Magnani B. Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am J Cardiol 1995;75(suppl):55A-62A.
11. Package insert. Flolan (epoprostenol). Research Triangle Park, NC: Burroughs Wellcome Co., 1995.
12. Campbell WB. Lipid-derived autocoids: eicosanoids and platelet-activating factor. In: Gilman AG, Goodman LS, Oilman A. eds. The pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1990: 600-11.
13. Rosenkranz B, Fischer C, Frolich JC. Prostacyclin metabolites in human plasma. Clin Pharmacol Ther 1981;29:420-4.
14. Jones DK, Higenbottam TW, Wallwork J. Treatment of primary pulmonary hypertension with intravenous epoprostenol (prostacyclin). Br Heart J 1987;57:270-8.
15. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Ann Intern Med 1990;112:485-91.
16. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409-15.
17. Higenbottam TW, Spiegelhalter D, Scott JP, Fuster V, Dinh-Xuan AT, Caine N, et al. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J 1993; 70:366-70.
18. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301.
19. Shapiro SM, Oudiz RJ, Tiesheng C, Romano MA, Beckman XJ, Georgiou D, et al. Primary pulmonary hypertension: improved long term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997;30:343-9.
20. McLaughlin VV, Genthner DE, Panella MM, Rich S, Reduction of pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338: 273-7.
21. Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 1982;66:334-8.
22. Higenbottam T, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984;1:1046-7.
23. Hinderliter AL, Willis PW, Barst RJ, Rich S, Rubin LJ, Badesch DB, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Circulation 1997;95:1479-86.